228 related articles for article (PubMed ID: 32369815)
21. Expert Discussion on Challenges in C3G Diagnosis: A Podcast Article on Best Practices in Kidney Biopsies.
Lafayette RA; Charu V
Adv Ther; 2023 Dec; 40(12):5557-5566. PubMed ID: 37751024
[TBL] [Abstract][Full Text] [Related]
22. C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies.
Caravaca-Fontán F; Lucientes L; Serra N; Cavero T; Rodado R; Ramos N; Gonzalez F; Shabaka A; Cabello V; Huerta A; Pampa-Saico S; Gutiérrez E; Quintana LF; López-Rubio ME; Draibe J; Alonso Titos J; Fernández-Juárez G; Goicoechea de Jorge E; Praga M
Nephrol Dial Transplant; 2022 Oct; 37(11):2128-2137. PubMed ID: 34677610
[TBL] [Abstract][Full Text] [Related]
23. C3 glomerulopathy in a patient with a history of post-infectious glomerulonephritis.
Nnadi N; Hendricks AR; Torrealba J; Drake KA; Gattineni J
Pediatr Nephrol; 2024 Mar; 39(3):745-748. PubMed ID: 37874356
[TBL] [Abstract][Full Text] [Related]
24. Eculizumab for treatment of rapidly progressive C3 glomerulopathy.
Le Quintrec M; Lionet A; Kandel C; Bourdon F; Gnemmi V; Colombat M; Goujon JM; Frémeaux-Bacchi V; Fakhouri F
Am J Kidney Dis; 2015 Mar; 65(3):484-9. PubMed ID: 25530108
[TBL] [Abstract][Full Text] [Related]
25. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
Noris M; Donadelli R; Remuzzi G
Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
[TBL] [Abstract][Full Text] [Related]
26. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion.
Sethi S; Nester CM; Smith RJ
Kidney Int; 2012 Mar; 81(5):434-41. PubMed ID: 22157657
[TBL] [Abstract][Full Text] [Related]
27. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis.
Xiao X; Pickering MC; Smith RJ
Semin Thromb Hemost; 2014 Jun; 40(4):465-71. PubMed ID: 24799308
[TBL] [Abstract][Full Text] [Related]
28. C3 glomerulopathy: Understanding an ultra-rare complement-mediated renal disease.
Heiderscheit AK; Hauer JJ; Smith RJH
Am J Med Genet C Semin Med Genet; 2022 Sep; 190(3):344-357. PubMed ID: 35734939
[TBL] [Abstract][Full Text] [Related]
29. Clinico-Pathogenic Similarities and Differences between Infection-Related Glomerulonephritis and C3 Glomerulopathy.
Wada Y; Kamata M; Miyasaka R; Abe T; Kawamura S; Takeuchi K; Aoyama T; Oda T; Takeuchi Y
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176142
[TBL] [Abstract][Full Text] [Related]
30. Kidney Transplantation in C3 Glomerulopathy: A Case Series.
Regunathan-Shenk R; Avasare RS; Ahn W; Canetta PA; Cohen DJ; Appel GB; Bomback AS
Am J Kidney Dis; 2019 Mar; 73(3):316-323. PubMed ID: 30413277
[TBL] [Abstract][Full Text] [Related]
31. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
[TBL] [Abstract][Full Text] [Related]
32. C3 Glomerulopathy: Pathogenesis and Treatment.
Ahmad SB; Bomback AS
Adv Chronic Kidney Dis; 2020 Mar; 27(2):104-110. PubMed ID: 32553242
[TBL] [Abstract][Full Text] [Related]
33. Gain-of-function factor H-related 5 protein impairs glomerular complement regulation resulting in kidney damage.
Malik TH; Gitterman DP; Lavin DP; Lomax-Browne HJ; Hiemeyer EC; Moran LB; Boroviak K; Cook HT; Gilmore AC; Mandwie M; Ahmad A; Alexander IE; Logan GJ; Marchbank KJ; Bradley A; Pickering MC
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33753502
[TBL] [Abstract][Full Text] [Related]
34. C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3- and C5-Convertases.
Zhao F; Afonso S; Lindner S; Hartmann A; Löschmann I; Nilsson B; Ekdahl KN; Weber LT; Habbig S; Schalk G; Kirschfink M; Zipfel PF; Skerka C
Front Immunol; 2019; 10():1030. PubMed ID: 31214159
[TBL] [Abstract][Full Text] [Related]
35. Humanized C3 Mouse: A Novel Accelerated Model of C3 Glomerulopathy.
Devalaraja-Narashimha K; Meagher K; Luo Y; Huang C; Kaplan T; Muthuswamy A; Halasz G; Casanova S; O'Brien J; Peyser Boiarsky R; McWhirter J; Gartner H; Bai Y; MacDonnell S; Liu C; Hu Y; Latuszek A; Wei Y; Prasad S; Huang T; Yancopoulos G; Murphy A; Olson W; Zambrowicz B; Macdonald L; Morton LG
J Am Soc Nephrol; 2021 Jan; 32(1):99-114. PubMed ID: 33288630
[TBL] [Abstract][Full Text] [Related]
36. Recurrent C3 glomerulopathy after kidney transplantation.
Obata S; Vaz de Castro PAS; Riella LV; Cravedi P
Transplant Rev (Orlando); 2024 Apr; 38(2):100839. PubMed ID: 38412598
[TBL] [Abstract][Full Text] [Related]
37. Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan.
Podos SD; Trachtman H; Appel GB; Bomback AS; Dixon BP; Wetzels JFM; Cook HT; Parikh SV; Pickering MC; Tumlin J; Langman CB; Lightstone L; Sperati CJ; Daina E; Bouman KP; Rice K; Thanassi JA; Huang M; Nester C; Remuzzi G
Am J Nephrol; 2022; 53(10):675-686. PubMed ID: 36404708
[TBL] [Abstract][Full Text] [Related]
38. Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.
Michels MAHM; van de Kar NCAJ; van den Bos RM; van der Velden TJAM; van Kraaij SAW; Sarlea SA; Gracchi V; Oosterveld MJS; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2019; 10():1350. PubMed ID: 31263464
[TBL] [Abstract][Full Text] [Related]
39. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
